Keros Therapeutics (KROS)
(Delayed Data from NSDQ)
$54.27 USD
-3.33 (-5.78%)
Updated May 10, 2024 04:00 PM ET
After-Market: $54.27 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Keros Therapeutics, Inc. [KROS]
Reports for Purchase
Showing records 41 - 50 ( 50 total )
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Data at ATS 2021 Furthers KER-012s Strong Pre-clinical Profile
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 MDS Data Remains Key Catalyst for Mid-21. Reit Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KER-050 MDS Data On-Track for Mid-21, Multiple Study Starts Define 2021. Reit Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ALK2 Inhibitor Data at ASH Highlight Broad Potential in Anemia and Cytopenias; PT to $100
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KROS Taking Steps Towards Proving Proof-of-Concept with Pipeline Advancements
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KER-047 First-in-Human Data Supports its Potential in Anemia and FOP; Reit Buy and $50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Strong Biomarker Data Package at EHA Derisks Upcoming in Patient Study; Reit Buy and $50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EHA Data Readout Sets Stage for the Planned Phase 2 Study in 2H20; Reit Buy and $50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Decoding TGF- â Signaling Conducive to Novel Therapies; Initiate With Buy and $50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A